01:48 , Mar 1, 2019 |  BC Innovations  |  Translation in Brief

Targeting pathogenic Th17 cells

A recent pair of studies offers two new approaches to treating autoimmune diseases that go after the source of Th17-mediated inflammation. T helper type 17 (Th17) cells are effector T cells that secrete the cytokine...
13:42 , Feb 12, 2019 |  BC Innovations  |  Translation in Brief

Stabilizing mutant proteins

A team from Novartis Institutes for BioMedical Research (NIBR) and University of British Columbia has hit upon a strategy for treating diseases caused by loss-of-function protein mutations: target allosteric pockets on the mutant proteins to...
16:00 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Immunodeficiency Cell culture studies identified two allosteric stabilizers of mutant MALT1 that could help treat combined immunodeficiency in patients harboring the loss-of-function W580S mutation of MALT1, which results in low B cell counts. In...
01:08 , Jan 4, 2019 |  BC Week In Review  |  Company News

AbbVie gets rights to Lupin's MALT1 program

Lupin Ltd. (NSE:LUPIN; BSE:500257) granted AbbVie Inc. (NYSE:ABBV) exclusive, worldwide rights to a portfolio of mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) inhibitors, which the U.S. pharma intends to develop for hematological cancers. AbbVie...
00:41 , Dec 25, 2018 |  BC Extra  |  Company News

AbbVie gets rights to Lupin's MALT1 program

Lupin Ltd. (NSE:LUPIN; BSE:500257) granted AbbVie Inc. (NYSE:ABBV) exclusive, worldwide rights to a portfolio of mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) inhibitors, which the U.S. pharma intends to develop for hematological cancers. AbbVie...
07:00 , Oct 22, 2015 |  BC Innovations  |  Translation in Brief

Unique ubiquity

A University of Lausanne team has turned to the U.K.'s MRC Technology for help in developing a therapeutic from the team's 2013 finding that monoubiquitination can activate the protease MALT1 in diffuse large B cell...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

MRC Technology, University of Lausanne deal

MRC Technology and the university partnered to develop small molecules inhibitors of mucosa associated lymphoid tissue lymphoma translocation protein 1 ( MALT1 ) to treat diffuse large B cell lymphoma. The immunomodulatory enzyme is required...
08:00 , Jan 22, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Epigenetic markers of susceptibility to type 2 diabetes

Bio Markers TECHNOLOGY: Gene profiling An epigenomic analysis of monozygotic twins identified markers of susceptibility to type 2 diabetes. The study examined pairs of adult monozygotic twins of three different types: pairs with type 2...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

AstraZeneca, Center for Drug Design and Discovery (CD3), Flanders Institute for Biotechnology (VIB) deal

AstraZeneca received exclusive, worldwide rights to develop and commercialize small molecule mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) inhibitors from life science research institute VIB and CD3. The partners hope to develop the...
08:00 , Feb 6, 2014 |  BC Innovations  |  Cover Story

Germinating MALT1

AstraZeneca plc has teamed up with the Flanders Institute for Biotechnology and the Centre for Drug Design and Discovery to make the first disclosed industry play for inhibitors of MALT1 . The deal announcement caps...